Credo Ventures

Credo Ventures has been one of the most consistently active early-stage investors in Central and Eastern Europe for more than a decade, operating from Prague with a portfolio that includes some of the most consequential European AI and software companies of the recent cycle. ElevenLabs is among the firms it backed early. The fund’s healthcare interest concentrates on AI/ML applications and digital health platforms with global ambitions from the start.

The Credo thesis has been remarkably consistent: write the first institutional check into technically ambitious CEE founders building category-defining companies. The firm has been willing to back generational AI platforms before they had the commercial traction that later-stage Western European or US funds require, which has produced an outsized share of the region’s most notable outcomes. In healthcare, the same logic applies. Credo looks for companies with credible technical defensibility, founding teams capable of operating globally, and end markets large enough to support a venture outcome. The portfolio leans technical and tends to favor AI/ML applications over service-heavy or single-market plays.

Credo writes pre-seed and seed checks, generally in the $1M to $5M range, with the willingness to lead at the seed stage and follow on into subsequent rounds. The check size at seed is larger than most CEE peers, which reflects the firm’s track record and its appetite for taking meaningful ownership in companies it has high conviction on. Geographically, the focus is CEE, with particular density in the Czech Republic, Slovakia, Hungary, Poland, Romania, and the Baltic states. Companies with CEE founders operating from the US or Western Europe remain in scope.

The partnership is one of the more experienced in the region, with partners who have been investing across multiple cycles and have the pattern recognition that comes from seeing many CEE companies through the full lifecycle. That experience translates into a diligence process that focuses on substance, with partners who engage directly with founders rather than handing off to associates.

Post-investment, Credo’s most distinctive value is its network of co-investors and follow-on funds. The firm has placed companies into Series A and beyond rounds led by top-tier London, Berlin, and US firms, and it actively manages those introductions. Board engagement is substantive but not micromanaging. For healthcare AI founders, Credo is most useful when the company has a strong technical core and global ambition rather than a regional service-business profile. The firm is less suited to founders who want deep clinical-regulatory specialism, which they will need to source through advisors. Founders considering Credo should plan for a substantive technical conversation, a partner who will hold the seat through the company’s growth, and a willingness to push for global scale rather than regional optimization. The fit is strongest for ambitious technical founders building AI-first companies with credible international markets in view.